However, clinical and preclinical studies have revealed that pharmacological inhibition of Bcl-2 and Bcl-xL alone in breast cancer cells causes the induction of Mcl1, which then leads to drug resistance and failure to inhibit tumor growth [5–7]. This evidence concerns the gene MCL1 and breast carcinoma.